Biomarker‐guided management reduces exacerbations in non‐eosinophilic asthma in pregnancy: A secondary analysis of a randomized controlled trial

Biomarker‐guided management reduces exacerbations in non‐eosinophilic asthma in pregnancy: A secondary analysis of a randomized controlled trial

ABSTRACT Background and objective The aim of this secondary analysis of a randomized controlled trial (RCT) of asthma management in pregnancy was to determine the treatment decision differences between a symptom control algorithm and a fractional exhaled nitric oxide (FENO)‐guided algorithm, and whe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respirology (Carlton, Vic.) Vic.), 2020-07, Vol.25 (7), p.719-725
Hauptverfasser: Murphy, Vanessa E., Porsbjerg, Celeste M., Robijn, Annelies L., Gibson, Peter G.
Format: Artikel
Sprache:eng
Schlagworte:
Algorithms
Asthma
Clinical trials
Control algorithms
Corticosteroids
eosinophils
Gestation
Leukocytes (eosinophilic)
Nitric oxide
phenotype
Phenotypes
Pregnancy
Respiratory diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Background and objective The aim of this secondary analysis of a randomized controlled trial (RCT) of asthma management in pregnancy was to determine the treatment decision differences between a symptom control algorithm and a fractional exhaled nitric oxide (FENO)‐guided algorithm, and whether the approach was effective in non‐eosinophilic asthma (NEA). Methods In this double‐blind parallel group RCT, women with asthma were randomized prior to 22 weeks gestation to treatment adjustment according to a symptom control algorithm (control group), or a FENO‐guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long‐acting beta‐agonist (LABA) added for uncontrolled symptoms). NEA was classified as baseline blood eosinophils
ISSN:1323-7799
1440-1843
DOI:10.1111/resp.13713